J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):330-335.e1. doi: 10.1016/j.japh.2022.10.012. Epub 2022 Oct 15.
Coronavirus disease 2019 (COVID-19) lockdowns disrupted access to harm reduction supplies and services known to be effective in overdose prevention and contributed to a worsening of the opioid crisis. However, because pharmacies can provide naloxone and sell over-the-counter (OTC) sterile syringes, their continued operation throughout the pandemic potentially reinforced a public health role as a distribution hub for safer use supplies.
The objective of this analysis was to examine patterns of naloxone and OTC syringe sale volume at 463 community pharmacies in 2 states with high overdose rates during the COVID-19 pandemic.
We analyzed weekly pharmacy-level dispensing data from January 5, 2020, to December 31, 2020, from one corporate community pharmacy chain in Massachusetts (n = 415 pharmacies) and New Hampshire (n = 48 pharmacies). Descriptive statistics and visualizations over the analytical period were generated as initial explorations of the outcome. Zero-inflated Poisson and negative binomial models were used to analyze distribution data along with county-level COVID-19 case rates and store-level COVID-19 testing location status during the same time. Interactions tested the effect of COVID-19 case rates on naloxone and OTC syringe sales.
Pharmacies that reported selling nonprescription syringes and dispensing naloxone during the study period averaged 210.13 OTC syringes sold and 0.53 naloxone prescriptions per week. Pharmacies in communities that experienced greater COVID-19 case burden also exhibited higher naloxone dispensing and OTC syringe sales during this period. The odds of selling OTC syringes increased over time but naloxone dispensing remained constant over the pandemic year. Pharmacies hosting COVID-19 testing tended to have lower OTC syringe sales and naloxone provision than nontesting sites.
During the COVID-19 pandemic, pharmacies provided harm reduction services and dispensed lifesaving medications by quickly adapting to fulfill community needs without disrupting co-located services for COVID-19 response.
2019 年冠状病毒病(COVID-19)封锁中断了获得已知可有效预防过量用药的减少伤害供应品和服务的途径,导致阿片类药物危机恶化。然而,由于药店可以提供纳洛酮并出售非处方(OTC)无菌注射器,因此在整个大流行期间,它们的持续运营可能加强了作为安全使用供应品分配中心的公共卫生作用。
本分析的目的是检查在 COVID-19 大流行期间,两个高过量用药率州的 463 家社区药店的纳洛酮和 OTC 注射器销售量模式。
我们分析了 2020 年 1 月 5 日至 2020 年 12 月 31 日期间马萨诸塞州(n=415 家)和新罕布什尔州(n=48 家)一家连锁社区药店的每周药店级别配药数据。在分析期间生成了描述性统计数据和可视化,作为对结果的初步探索。使用零膨胀泊松和负二项式模型来分析分布数据以及同一时期的县一级 COVID-19 病例率和商店一级 COVID-19 检测位置状态。交互作用测试了 COVID-19 病例率对纳洛酮和 OTC 注射器销售的影响。
在研究期间报告销售非处方注射器和配药纳洛酮的药店平均每周销售 210.13 支 OTC 注射器和 0.53 份纳洛酮处方。在经历更大 COVID-19 病例负担的社区中的药店在此期间也表现出更高的纳洛酮配药和 OTC 注射器销售。销售 OTC 注射器的几率随着时间的推移而增加,但在整个大流行年期间,纳洛酮的配药保持不变。与非检测地点相比,举办 COVID-19 检测的药店的 OTC 注射器销售和纳洛酮供应较低。
在 COVID-19 大流行期间,药店通过快速适应满足社区需求提供了减少伤害服务,并提供了救生药物,而不会中断 COVID-19 应对措施的同时提供的其他服务。